These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28474460)

  • 21. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients.
    Guerriero F; Sgarlata C; Marcassa C; Ricevuti G; Rollone M
    Clin Interv Aging; 2015; 10():1-11. PubMed ID: 25565782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
    Morlion B; Clemens KE; Dunlop W
    Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.
    Oertel WH; Hallström Y; Saletu-Zyhlarz GM; Hopp M; Bosse B; Trenkwalder C;
    CNS Drugs; 2016 Aug; 30(8):749-60. PubMed ID: 27401882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
    Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K
    Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
    Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
    Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
    Hermanns K; Junker U; Nolte T
    Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
    Trenkwalder C; Chaudhuri KR; Martinez-Martin P; Rascol O; Ehret R; Vališ M; Sátori M; Krygowska-Wajs A; Marti MJ; Reimer K; Oksche A; Lomax M; DeCesare J; Hopp M;
    Lancet Neurol; 2015 Dec; 14(12):1161-70. PubMed ID: 26494524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial.
    Oppermann J; Bredow J; Spies CK; Lemken J; Unglaub F; Boese CK; Dargel J; Eysel P; Zöllner J
    J Clin Anesth; 2016 Sep; 33():491-7. PubMed ID: 27555214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
    van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
    Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study.
    Hesselbarth S; Löwenstein O; Cegla T
    Scand J Pain; 2014 Apr; 5(2):75-81. PubMed ID: 29913668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
    Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.
    Löwenstein O; Leyendecker P; Lux EA; Blagden M; Simpson KH; Hopp M; Bosse B; Reimer K
    BMC Clin Pharmacol; 2010 Sep; 10():12. PubMed ID: 20920236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
    Clemens KE; Quednau I; Klaschik E
    Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain.
    Madeo G; Schirinzi T; Natoli S; Pierantozzi M; Stefani A; Dauri M; Pisani A
    J Neurol; 2015 Sep; 262(9):2164-70. PubMed ID: 26134157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.
    Cuomo A; Russo G; Esposito G; Forte CA; Connola M; Marcassa C
    Am J Hosp Palliat Care; 2014 Dec; 31(8):867-76. PubMed ID: 24249829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
    Dunlop W; Uhl R; Khan I; Taylor A; Barton G
    J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence.
    Morlion BJ; Mueller-Lissner SA; Vellucci R; Leppert W; Coffin BC; Dickerson SL; O'Brien T
    Pain Pract; 2018 Jun; 18(5):647-665. PubMed ID: 28944983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.